Progress and prospects for blood-stage malaria vaccines

Modeling malaria in humanized mice: opportunities and challenges

(2015) Evelyn Siu et al.   Annals of the New York Academy of Sciences

The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines

(2015) Holger Spiegel et al.   Biotechnology Journal

CD14hiCD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so

(2015) Jingling Zhou et al.   BMC Medicine

A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys

(2015) Alexander D. Douglas et al.   Cell Host & Microbe

Developing vaccines to prevent malaria in pregnant women

(2015) Nicaise Tuikue-Ndam et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria

(2015) Michelle J. Boyle et al.   IMMUNITY

Multiple Plasmodium falciparum Erythrocyte Membrane Protein 1 Variants per Genome Can Bind IgM via Its Fc Fragment Fcμ

(2015) Anine Jeppesen et al.   INFECTION AND IMMUNITY

Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria

(2015) Jing Huang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Mapping the Binding Site of a Cross-ReactivePlasmodium falciparumPfEMP1 Monoclonal Antibody Inhibitory of ICAM-1 Binding

(2015) Frank Lennartz et al.   JOURNAL OF IMMUNOLOGY

Antibodies to thePlasmodium falciparumProteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit Parasite Growth, and Predict Protection From Clinical Malaria

(2015) Chris Y. H. Chiu et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

(2015) Michael T White et al.   LANCET INFECTIOUS DISEASES

Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines

(2015) Danielle I Stanisic et al.   MALARIA JOURNAL

The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015

(2015) S. Bhatt et al.   NATURE

Landmark green light for Mosquirix malaria vaccine

(2015) Chris Morrison   NATURE BIOTECHNOLOGY

Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate—Tackling the Cocktail Challenge

(2015) Alexander Boes et al.   PLoS One

Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial forPlasmodium falciparumerythrocyte invasion

(2015) K. Sony Reddy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap

(2015) David C. Kaslow et al.   VACCINE

Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model

(2015) Susanna Dunachie et al.   VACCINE

Development of vaccines for Plasmodium vivax malaria

(2015) Ivo Mueller et al.   VACCINE

Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria

(2015) David Llewellyn et al.   Scientific Reports

The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines

(2015) Holger Spiegel et al.   Biotechnology Journal

Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175

(2015) Chetan E. Chitnis et al.   PLoS One

Immunogenicity of the Plasmodium falciparum PfEMP1-VarO Adhesin: Induction of Surface-Reactive and Rosette-Disrupting Antibodies to VarO Infected Erythrocytes

(2015) Micheline Guillotte et al.   PLoS One

Opsonic phagocytosis of Plasmodium falciparummerozoites: mechanism in human immunity and a correlate of protection against malaria

(2014) Faith HA Osier et al.   BMC Medicine

Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates

(2014) Jo-Anne Chan et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1

(2014) Karen S. Harris et al.   INFECTION AND IMMUNITY

Comparison of Biological Activity of Human Anti-Apical Membrane Antigen-1 Antibodies Induced by Natural Infection and Vaccination

(2014) K. Miura et al.   JOURNAL OF IMMUNOLOGY

High-throughput tri-colour flow cytometry technique to assess Plasmodium falciparum parasitaemia in bioassays

(2014) Regis W Tiendrebeogo et al.   MALARIA JOURNAL

A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein

(2014) Rosalynn L Ord et al.   MALARIA JOURNAL

PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen

(2014) Xin Zhao et al.   MALARIA JOURNAL

Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria

(2014) Wathsala Wijayalath et al.   MALARIA JOURNAL

Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial

(2014) Susanne H Hodgson et al.   MOLECULAR THERAPY

Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies

(2014) Katherine E. Wright et al.   NATURE

Using the PfEMP1 Head Structure Binding Motif to Deal a Blow at Severe Malaria

(2014) Manuel E. Patarroyo et al.   PLoS One

Protective Epitopes of the Plasmodium falciparum SERA5 Malaria Vaccine Reside in Intrinsically Unstructured N-Terminal Repetitive Sequences

(2014) Masanori Yagi et al.   PLoS One

Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria

(2014) P. Srinivasan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human natural killer cells control Plasmodium falciparum infection by eliminating infected red blood cells

(2014) Q. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection

(2014) D. K. Raj et al.   SCIENCE

New antigens for a multicomponent blood-stage malaria vaccine

(2014) F. H. Osier et al.   Science Translational Medicine

A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages

(2014) Michael Theisen et al.   VACCINE

Breadth of Anti-Merozoite Antibody Responses Is Associated With the Genetic Diversity of Asymptomatic Plasmodium falciparum Infections and Protection Against Clinical Malaria

(2013) Josea Rono et al.   CLINICAL INFECTIOUS DISEASES

RALP1 Is a Rhoptry Neck Erythrocyte-Binding Protein of Plasmodium falciparum Merozoites and a Potential Blood-Stage Vaccine Candidate Antigen

(2013) Daisuke Ito et al.   INFECTION AND IMMUNITY

Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1

(2013) Kazutoyo Miura et al.   INFECTION AND IMMUNITY

Bacterially Expressed Full-Length Recombinant Plasmodium falciparum RH5 Protein Binds Erythrocytes and Elicits Potent Strain-Transcending Parasite-Neutralizing Antibodies

(2013) K. Sony Reddy et al.   INFECTION AND IMMUNITY

Cross-species malaria immunity induced by chemically attenuated parasites

(2013) Michael F. Good et al.   JOURNAL OF CLINICAL INVESTIGATION

Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5

(2013) A. D. Douglas et al.   JOURNAL OF IMMUNOLOGY

Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development

(2013) J. S. Richards et al.   JOURNAL OF IMMUNOLOGY

Naturally Acquired Antibodies Specific for Plasmodium falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection From Malaria

(2013) Tuan M. Tran et al.   JOURNAL OF INFECTIOUS DISEASES

Plasmodium falciparum Merozoite Surface Antigen, PfRH5, Elicits Detectable Levels of Invasion-Inhibiting Antibodies in Humans

(2013) Saurabh D. Patel et al.   JOURNAL OF INFECTIOUS DISEASES

The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas

(2013) Micha Phill Grønholm Jepsen, Prajakta S. Jogdand, Susheel K. Singh, Meral Esen, Michael Christiansen, Saadou Issifou, Aurore B. Hounkpatin, Ulysse Ateba-Ngoa, Peter G. Kremsner, Morten H. Dziegiel, Severin Olesen-Larsen et al.   JOURNAL OF INFECTIOUS DISEASES

Malaria

(2013) Nicholas J White et al.   LANCET

Analysis of antibody induction upon immunization with distinct NTS-DBL1α-domains of PfEMP1 from rosetting Plasmodium falciparum parasites

(2013) Davide Angeletti et al.   MALARIA JOURNAL

Structure-Function-Immunogenicity Studies of PfEMP1 Domain DBL2βPF11_0521, a Malaria Parasite Ligand for ICAM-1

(2013) Justin Gullingsrud et al.   PLoS One

Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36

(2013) Nirianne Marie Q. Palacpac et al.   PLoS One

Vaccination with Conserved Regions of Erythrocyte-Binding Antigens Induces Neutralizing Antibodies against Multiple Strains of Plasmodium falciparum

(2013) Julie Healer et al.   PLoS One

Opsonising Antibodies to P. falciparum Merozoites Associated with Immunity to Clinical Malaria

(2013) Danika L. Hill et al.   PLoS One

Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

(2013) Matthew B. Laurens et al.   PLoS One

Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

(2013) R. A. Seder et al.   SCIENCE

Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

(2013) Cindy Tamminga et al.   Human Vaccines & Immunotherapeutics

Challenges of assessing the clinical efficacy of asexual blood-stagePlasmodium falciparummalaria vaccines

(2013) Susanne H Sheehy et al.   Human Vaccines & Immunotherapeutics

Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1

(2013) Sheetij Dutta et al.   PLoS Pathogens

Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity

(2012) Jo-Anne Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

A Novel Domain Cassette Identifies Plasmodium falciparum PfEMP1 Proteins Binding ICAM-1 and Is a Target of Cross-Reactive, Adhesion-Inhibitory Antibodies

(2012) A. Bengtsson et al.   JOURNAL OF IMMUNOLOGY

NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections

(2012) Anne C. Teirlinck et al.   JOURNAL OF INFECTIOUS DISEASES

Identification of a specific region of Plasmodium falciparum EBL-1 that binds to host receptor glycophorin B and inhibits merozoite invasion in human red blood cells

(2012) Xuerong Li et al.   MOLECULAR AND BIOCHEMICAL PARASITOLOGY

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

(2012) Susanne H Sheehy et al.   MOLECULAR THERAPY

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

Cell Biological Characterization of the Malaria Vaccine Candidate Trophozoite Exported Protein 1

(2012) Caroline Kulangara et al.   PLoS One

Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria

(2012) Ruth D. Ellis et al.   PLoS One

Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria

(2012) Damien R. Drew et al.   PLoS One

Experimentally induced blood stage malaria infection as a tool for clinical research

(2012) Christian R. Engwerda et al.   TRENDS IN PARASITOLOGY

Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes

(2012) Hirokazu Sakamoto et al.   VACCINE

A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants

(2012) Leyla Y. Bustamante et al.   VACCINE

Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

(2012) Christopher J.A. Duncan et al.   Human Vaccines & Immunotherapeutics

Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens

(2012) Andrew R. Williams et al.   PLoS Pathogens

Discovery of GAMA, a Plasmodium falciparum Merozoite Micronemal Protein, as a Novel Blood-Stage Vaccine Candidate Antigen

(2011) Thangavelu U. Arumugam et al.   INFECTION AND IMMUNITY

Plasmodium falciparum 19-Kilodalton Merozoite Surface Protein 1 (MSP1)-Specific Antibodies That Interfere with Parasite GrowthIn VitroCan Inhibit MSP1 Processing, Merozoite Invasion, and Intracellular Parasite Development

(2011) David K. Moss et al.   INFECTION AND IMMUNITY

The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes

(2011) Harini D de Silva et al.   MALARIA JOURNAL

Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits

(2011) Kwadwo A Kusi et al.   MALARIA JOURNAL

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques

(2011) Kwadwo A Kusi et al.   MALARIA JOURNAL

Protection against Malaria by MSP3 Candidate Vaccine

(2011) Sodiomon B. Sirima et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Field Trial to Assess a Blood-Stage Malaria Vaccine

(2011) Mahamadou A. Thera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunisation with Recombinant PfEMP1 Domains Elicits Functional Rosette-Inhibiting and Phagocytosis-Inducing Antibodies to Plasmodium falciparum

(2011) Ashfaq Ghumra et al.   PLoS One

Non-Apical Membrane Antigen 1 (AMA1) IgGs from Malian Children Interfere with Functional Activity of AMA1 IgGs as Judged by Growth Inhibition Assay

(2011) Kazutoyo Miura et al.   PLoS One

A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children

(2011) Sabine Bélard et al.   PLoS One

Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children

(2011) Patrick Georges Cech et al.   PLoS One

A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720

(2011) James S. McCarthy et al.   PLoS One

Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909

(2011) Christopher J. A. Duncan et al.   PLoS One

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

(2011) Martha Sedegah et al.   PLoS One

Pf332-C231-reactive antibodies affect growth and development of intra-erythrocytic Plasmodium falciparum parasites

(2011) Halima A. Balogun et al.   VACCINE

Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized

(2011) Kazutoyo Miura et al.   VACCINE

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

(2011) Alexander D. Douglas et al.   Nature Communications

An EGF-like Protein Forms a Complex with PfRh5 and Is Required for Invasion of Human Erythrocytes by Plasmodium falciparum

(2011) Lin Chen et al.   PLoS Pathogens

Safety and Immunogenicity of a Recombinant Nonglycosylated Erythrocyte Binding Antigen 175 Region II Malaria Vaccine in Healthy Adults Living in an Area Where Malaria Is Not Endemic

(2010) H. M. El Sahly et al.   Clinical and Vaccine Immunology

Association between Naturally Acquired Antibodies to Erythrocyte‐Binding Antigens ofPlasmodium falciparumand Protection from Malaria and High‐Density Parasitemia

(2010) Jack S. Richards et al.   CLINICAL INFECTIOUS DISEASES

Five year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

(2010) Kalifa Bojang et al.   Human vaccines & immunotherapeutics

Interaction betweenPlasmodium falciparumApical Membrane Antigen 1 and the Rhoptry Neck Protein Complex Defines a Key Step in the Erythrocyte Invasion Process of Malaria Parasites

(2010) Dave Richard et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine

(2010) Amed Ouattara et al.   MALARIA JOURNAL

Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36

(2010) Toshihiro Horii et al.   PARASITOLOGY INTERNATIONAL

Clinical Protection from Falciparum Malaria Correlates with Neutrophil Respiratory Bursts Induced by Merozoites Opsonized with Human Serum Antibodies

(2010) Charlotte Joos et al.   PLoS One

Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

(2010) Ruth D. Ellis et al.   PLoS One

A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray

(2010) P. D. Crompton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development

(2010) M. J. Boyle et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

(2010) Benjamin Mordmüller et al.   VACCINE

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

(2010) Mark A. Pierce et al.   VACCINE

The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis

(2010) Freya J. I. Fowkes et al.   PLOS MEDICINE

Vaccine Potentials of an Intrinsically Unstructured Fragment Derived from the Blood Stage-Associated Plasmodium falciparum Protein PFF0165c

(2009) S. Olugbile et al.   INFECTION AND IMMUNITY

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso

(2009) I. NEBIE et al.   PARASITE IMMUNOLOGY

Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya

(2009) Bernhards R. Ogutu et al.   PLoS One

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

(2009) Michele D. Spring et al.   PLoS One

High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model

(2009) Sheetij Dutta et al.   PLoS One

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

(2009) Issaka Sagara et al.   VACCINE

Safety and immunogenicity of GMZ2 — a MSP3–GLURP fusion protein malaria vaccine candidate

(2009) Meral Esen et al.   VACCINE

A Distinct Peripheral Blood Monocyte Phenotype Is Associated with Parasite Inhibitory Activity in Acute Uncomplicated Plasmodium falciparum Malaria

(2009) Pattamawan Chimma et al.   PLoS Pathogens

Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites

(2008) Paul R. Gilson et al.   INTERNATIONAL JOURNAL FOR PARASITOLOGY

Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure

(2008) Chiawei W. Tsai et al.   MOLECULAR AND BIOCHEMICAL PARASITOLOGY

Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial

(2008) Mahamadou A. Thera et al.   PLoS One

Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial

(2008) Fiona M. Thompson et al.   PLoS One

Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults

(2008) Jinhong Hu et al.   PLoS One

Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses

(2008) Jeffrey A. Lyon et al.   PLoS One

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

(2008) Gregory E. D. Mullen et al.   PLoS One

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

(2008) Meta Roestenberg et al.   PLoS One

A Phase 1 trial of PfCP2.9: An AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

(2008) Elissa Malkin et al.   VACCINE